Table 1.
Cytochrome enzyme | Antipsychotic | Serum antipsychotic level PM compared to EM | Serum antipsychotic level UM compared to EM | Metabolizer group associated with TD |
---|---|---|---|---|
CYP2D6 | Aripiprazole | 60% higher serum level46, 1.6 fold increase in active metabolite46,47 | NSD | |
Clozapine | No difference47,156–158 | No difference157,158 | NSD | |
Haloperidol | Increased serum haloperidol and metabolite levels38–42,44,45,159 | No association with TD44 | ||
Risperidone | Increased serum risperidone42,48 | No association with TD58,59 | ||
Zuclopenthixol | 1.6–2 fold increased serum level49–52 | Conflicting results. PM associated with TD in one study,51 another found no association with TD58,59 | ||
Perphenazine | 2.9–4 fold increased serum level54,160 | No association with TD58,59 | ||
Thioridazine | 1.8–4.5 fold increased serum level55–57 | NSD | ||
Olanzapine | No difference161 | No association with TD58,59 | ||
CYP1A2 | Olanzapine | No difference161 | No association with TD58,59 | |
CYP3A4 | Thioridazine | 1.8–4.5 fold increase serum level55–57 | NSD | |
Aripiprazole | 1.5–1.8 fold increase in serum level, 1.6 fold increase in active metabolite46 | NSD | ||
Ziprasidone | NSD | NSD | ||
Olanzapine | NSD | Subtherapeutic serum olanzapine level162 | NSD |
Abbreviations: PM, poor metabolizer; EM, extensive metabolizer; UM, ultrafast metabolizer; TD, tardive dyskinesia; NSD, no studies done.